Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at ...